Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Mar;59(3):434–438. doi: 10.1038/bjc.1989.88

The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation.

P J Selby 1, R L Powles 1, D Easton 1, T J Perren 1, K Stolle 1, B Jameson 1, A P Fiddian 1, Y Tryhorn 1, H Stern 1
PMCID: PMC2247066  PMID: 2539180

Abstract

Eighty-two patients were randomly allocated to receive intravenous acyclovir 5 mg kg-1 t.d.s. for 23 days followed by oral acyclovir 800 mg 6-hourly for 6 months or matching placebos after allogeneic bone marrow transplantation. Herpes simplex and varicella zoster virus infections were significantly reduced during the period of administration of acyclovir. No reduction in cytomegalovirus infection was demonstrated. The drug was not toxic.

Full text

PDF
434

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balfour H. H., Jr, Bean B., Laskin O. L., Ambinder R. F., Meyers J. D., Wade J. C., Zaia J. A., Aeppli D., Kirk L. E., Segreti A. C. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med. 1983 Jun 16;308(24):1448–1453. doi: 10.1056/NEJM198306163082404. [DOI] [PubMed] [Google Scholar]
  2. Freedman L. S., White S. J. On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics. 1976 Sep;32(3):691–694. [PubMed] [Google Scholar]
  3. Gluckman E., Lotsberg J., Devergie A., Zhao X. M., Melo R., Gomez-Morales M., Nebout T., Mazeron M. C., Perol Y. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet. 1983 Sep 24;2(8352):706–708. doi: 10.1016/s0140-6736(83)92248-1. [DOI] [PubMed] [Google Scholar]
  4. Hann I. M., Prentice H. G., Blacklock H. A., Ross M. G., Brigden D., Rosling A. E., Burke C., Crawford D. H., Brumfitt W., Hoffbrand A. V. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. Br Med J (Clin Res Ed) 1983 Aug 6;287(6389):384–388. doi: 10.1136/bmj.287.6389.384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Harada S., Agarwal D. P., Goedde H. W., Tagaki S., Ishikawa B. Possible protective role against alcoholism for aldehyde dehydrogenase isozyme deficiency in Japan. Lancet. 1982 Oct 9;2(8302):827–827. doi: 10.1016/s0140-6736(82)92722-2. [DOI] [PubMed] [Google Scholar]
  6. Locksley R. M., Flournoy N., Sullivan K. M., Meyers J. D. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985 Dec;152(6):1172–1181. doi: 10.1093/infdis/152.6.1172. [DOI] [PubMed] [Google Scholar]
  7. Lundgren G., Wilczek H., Lönnqvist B., Lindholm A., Wahren B., Ringdén O. Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis Suppl. 1985;47:137–144. [PubMed] [Google Scholar]
  8. McKendrick M. W., McGill J. I., White J. E., Wood M. J. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed) 1986 Dec 13;293(6561):1529–1532. doi: 10.1136/bmj.293.6561.1529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Meyers J. D., Wade J. C., Mitchell C. D., Saral R., Lietman P. S., Durack D. T., Levin M. J., Segreti A. C., Balfour H. H., Jr Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med. 1982 Jul 20;73(1A):229–235. doi: 10.1016/0002-9343(82)90097-3. [DOI] [PubMed] [Google Scholar]
  10. Prentice H. G., Hann I. M. Antiviral therapy in the immunocompromised patient. Br Med Bull. 1985 Oct;41(4):367–373. doi: 10.1093/oxfordjournals.bmb.a072078. [DOI] [PubMed] [Google Scholar]
  11. Saral R., Burns W. H., Laskin O. L., Santos G. W., Lietman P. S. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med. 1981 Jul 9;305(2):63–67. doi: 10.1056/NEJM198107093050202. [DOI] [PubMed] [Google Scholar]
  12. Selby P., Powles R. L., Blake S., Stolle K., Mbidde E. K., McElwain T. J., Hickmott E., Whiteman P. D. Amino (hydroxyethoxymethyl) purine: a new well-absorbed prodrug of acyclovir. Lancet. 1984 Dec 22;2(8417-8418):1428–1430. doi: 10.1016/s0140-6736(84)91624-6. [DOI] [PubMed] [Google Scholar]
  13. Shepp D. H., Dandliker P. S., Flournoy N., Meyers J. D. Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients. Transplantation. 1987 May;43(5):654–658. doi: 10.1097/00007890-198705000-00010. [DOI] [PubMed] [Google Scholar]
  14. Straus S. E., Rooney J. F., Sever J. L., Seidlin M., Nusinoff-Lehrman S., Cremer K. NIH Conference. Herpes simplex virus infection: biology, treatment, and prevention. Ann Intern Med. 1985 Sep;103(3):404–419. doi: 10.7326/0003-4819-103-3-404. [DOI] [PubMed] [Google Scholar]
  15. Wade J. C., Newton B., Flournoy N., Meyers J. D. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med. 1984 Jun;100(6):823–828. doi: 10.7326/0003-4819-100-6-823. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES